Do analysts recommend XCUR or FLGC?

Flora Growth has a consensus target price of $30.00, indicating a potential upside of 557.89%. Given Flora Growth's stronger consensus rating and higher probable upside, analysts clearly believe Flora Growth is more favorable than Exicure. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Exicure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Flora Growth 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is XCUR or FLGC more profitable?

Exicure has a net margin of 0.00% compared to Flora Growth's net margin of -32.03%. Flora Growth's return on equity of -64.02% beat Exicure's return on equity. Company Net Margins Return on Equity Return on Assets Exicure N/A -179.41% -64.37% Flora Growth -32.03% -64.02% -34.46%

Is MDCX or FLGC more profitable?

Medicus Pharma has a net margin of 0.00% compared to Flora Growth's net margin of -32.03%. Flora Growth's return on equity of -64.02% beat Medicus Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Medicus Pharma N/A -3,137.84% -311.33% Flora Growth -32.03% -64.02% -34.46%

Which has preferable valuation and earnings, KZIA or FLGC?

Novogen has higher earnings, but lower revenue than Flora Growth. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novogen $30K 759.55 -$13.41M N/A N/A Flora Growth $57.61M 0.08 -$15.91M -$32.49 N/A

Is KZIA or FLGC more profitable?

Novogen has a net margin of 0.00% compared to Flora Growth's net margin of -32.03%. Novogen's return on equity of 0.00% beat Flora Growth's return on equity. Company Net Margins Return on Equity Return on Assets Novogen N/A N/A N/A Flora Growth -32.03% -64.02% -34.46%

Do analysts recommend TPST or FLGC?

Flora Growth has a consensus target price of $30.00, indicating a potential upside of 557.89%. Given Flora Growth's stronger consensus rating and higher probable upside, analysts plainly believe Flora Growth is more favorable than Tempest Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tempest Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Flora Growth 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Flora Growth (FLGC) Competitors

$4.56 -0.33 (-6.72%)

As of 06/12/2026

Compare

FLGC vs. XCUR, MDCX, KZIA, TPST, and HOWL

Should you buy Flora Growth stock or one of its competitors? MarketBeat compares Flora Growth with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Flora Growth include Exicure (XCUR), Medicus Pharma (MDCX), Novogen (KZIA), Tempest Therapeutics (TPST), and Werewolf Therapeutics (HOWL). These companies are all part of the "pharmaceutical products" industry.

How does Flora Growth compare to Exicure?

Exicure (NASDAQ:XCUR) and Flora Growth (NASDAQ:FLGC) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, dividends, analyst recommendations, earnings and profitability.

Flora Growth has a consensus target price of $30.00, indicating a potential upside of 557.89%. Given Flora Growth's stronger consensus rating and higher probable upside, analysts clearly believe Flora Growth is more favorable than Exicure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exicure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Flora Growth	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

42.8% of Exicure shares are owned by institutional investors. Comparatively, 36.0% of Flora Growth shares are owned by institutional investors. 52.8% of Exicure shares are owned by insiders. Comparatively, 2.3% of Flora Growth shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Exicure has higher earnings, but lower revenue than Flora Growth. Exicure is trading at a lower price-to-earnings ratio than Flora Growth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exicure	$500K	39.37	-$4.95M	-$1.55	N/A
Flora Growth	$57.61M	0.08	-$15.91M	-$32.49	N/A

Exicure has a beta of 3.53, meaning that its stock price is 253% more volatile than the broader market. Comparatively, Flora Growth has a beta of 1.9, meaning that its stock price is 90% more volatile than the broader market.

In the previous week, Exicure had 5 more articles in the media than Flora Growth. MarketBeat recorded 5 mentions for Exicure and 0 mentions for Flora Growth. Exicure's average media sentiment score of 0.57 beat Flora Growth's score of 0.00 indicating that Exicure is being referred to more favorably in the media.

Company	Overall Sentiment
Exicure	Positive
Flora Growth	Neutral

Exicure has a net margin of 0.00% compared to Flora Growth's net margin of -32.03%. Flora Growth's return on equity of -64.02% beat Exicure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exicure	N/A	-179.41%	-64.37%
Flora Growth	-32.03%	-64.02%	-34.46%

Summary

Exicure beats Flora Growth on 9 of the 16 factors compared between the two stocks.

How does Flora Growth compare to Medicus Pharma?

Medicus Pharma (NASDAQ:MDCX) and Flora Growth (NASDAQ:FLGC) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, risk, dividends, valuation, media sentiment and earnings.

Medicus Pharma has a net margin of 0.00% compared to Flora Growth's net margin of -32.03%. Flora Growth's return on equity of -64.02% beat Medicus Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medicus Pharma	N/A	-3,137.84%	-311.33%
Flora Growth	-32.03%	-64.02%	-34.46%

Medicus Pharma has a beta of 0.12, meaning that its share price is 88% less volatile than the broader market. Comparatively, Flora Growth has a beta of 1.9, meaning that its share price is 90% more volatile than the broader market.

36.0% of Flora Growth shares are held by institutional investors. 8.1% of Medicus Pharma shares are held by insiders. Comparatively, 2.3% of Flora Growth shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Flora Growth has higher revenue and earnings than Medicus Pharma. Flora Growth is trading at a lower price-to-earnings ratio than Medicus Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medicus Pharma	N/A	N/A	-$35.46M	-$2.68	N/A
Flora Growth	$57.61M	0.08	-$15.91M	-$32.49	N/A

In the previous week, Medicus Pharma had 7 more articles in the media than Flora Growth. MarketBeat recorded 7 mentions for Medicus Pharma and 0 mentions for Flora Growth. Medicus Pharma's average media sentiment score of 0.30 beat Flora Growth's score of 0.00 indicating that Medicus Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
Medicus Pharma	Neutral
Flora Growth	Neutral

Medicus Pharma presently has a consensus price target of $9.00, suggesting a potential upside of 2,586.57%. Flora Growth has a consensus price target of $30.00, suggesting a potential upside of 557.89%. Given Medicus Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Medicus Pharma is more favorable than Flora Growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medicus Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Flora Growth	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Medicus Pharma beats Flora Growth on 9 of the 15 factors compared between the two stocks.

How does Flora Growth compare to Novogen?

Novogen (NASDAQ:KZIA) and Flora Growth (NASDAQ:FLGC) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, analyst recommendations, institutional ownership, media sentiment, risk and valuation.

Novogen has a net margin of 0.00% compared to Flora Growth's net margin of -32.03%. Novogen's return on equity of 0.00% beat Flora Growth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novogen	N/A	N/A	N/A
Flora Growth	-32.03%	-64.02%	-34.46%

Novogen has higher earnings, but lower revenue than Flora Growth.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novogen	$30K	759.55	-$13.41M	N/A	N/A
Flora Growth	$57.61M	0.08	-$15.91M	-$32.49	N/A

Novogen presently has a consensus target price of $23.75, indicating a potential upside of 71.98%. Flora Growth has a consensus target price of $30.00, indicating a potential upside of 557.89%. Given Flora Growth's higher probable upside, analysts plainly believe Flora Growth is more favorable than Novogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novogen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Flora Growth	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Novogen had 3 more articles in the media than Flora Growth. MarketBeat recorded 3 mentions for Novogen and 0 mentions for Flora Growth. Novogen's average media sentiment score of 0.96 beat Flora Growth's score of 0.00 indicating that Novogen is being referred to more favorably in the media.

Company	Overall Sentiment
Novogen	Positive
Flora Growth	Neutral

Novogen has a beta of 2.17, indicating that its stock price is 117% more volatile than the broader market. Comparatively, Flora Growth has a beta of 1.9, indicating that its stock price is 90% more volatile than the broader market.

30.9% of Novogen shares are held by institutional investors. Comparatively, 36.0% of Flora Growth shares are held by institutional investors. 1.0% of Novogen shares are held by company insiders. Comparatively, 2.3% of Flora Growth shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Novogen beats Flora Growth on 10 of the 14 factors compared between the two stocks.

How does Flora Growth compare to Tempest Therapeutics?

Tempest Therapeutics (NASDAQ:TPST) and Flora Growth (NASDAQ:FLGC) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership and valuation.

Flora Growth has higher revenue and earnings than Tempest Therapeutics. Tempest Therapeutics is trading at a lower price-to-earnings ratio than Flora Growth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tempest Therapeutics	N/A	N/A	-$26.26M	-$6.01	N/A
Flora Growth	$57.61M	0.08	-$15.91M	-$32.49	N/A

22.5% of Tempest Therapeutics shares are owned by institutional investors. Comparatively, 36.0% of Flora Growth shares are owned by institutional investors. 36.3% of Tempest Therapeutics shares are owned by company insiders. Comparatively, 2.3% of Flora Growth shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Tempest Therapeutics has a net margin of 0.00% compared to Flora Growth's net margin of -32.03%. Flora Growth's return on equity of -64.02% beat Tempest Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tempest Therapeutics	N/A	-355.61%	-121.21%
Flora Growth	-32.03%	-64.02%	-34.46%

In the previous week, Tempest Therapeutics had 1 more articles in the media than Flora Growth. MarketBeat recorded 1 mentions for Tempest Therapeutics and 0 mentions for Flora Growth. Tempest Therapeutics' average media sentiment score of 1.87 beat Flora Growth's score of 0.00 indicating that Tempest Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Tempest Therapeutics	Very Positive
Flora Growth	Neutral

Flora Growth has a consensus target price of $30.00, indicating a potential upside of 557.89%. Given Flora Growth's stronger consensus rating and higher probable upside, analysts plainly believe Flora Growth is more favorable than Tempest Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tempest Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Flora Growth	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Tempest Therapeutics has a beta of -1.85, indicating that its stock price is 285% less volatile than the broader market. Comparatively, Flora Growth has a beta of 1.9, indicating that its stock price is 90% more volatile than the broader market.

Summary

Flora Growth beats Tempest Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Flora Growth compare to Werewolf Therapeutics?

Flora Growth (NASDAQ:FLGC) and Werewolf Therapeutics (NASDAQ:HOWL) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.

Werewolf Therapeutics has a net margin of 0.00% compared to Flora Growth's net margin of -32.03%. Flora Growth's return on equity of -64.02% beat Werewolf Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Flora Growth	-32.03%	-64.02%	-34.46%
Werewolf Therapeutics	N/A	-208.23%	-75.12%

Flora Growth has a beta of 1.9, suggesting that its share price is 90% more volatile than the broader market. Comparatively, Werewolf Therapeutics has a beta of 0.29, suggesting that its share price is 71% less volatile than the broader market.

36.0% of Flora Growth shares are held by institutional investors. Comparatively, 64.8% of Werewolf Therapeutics shares are held by institutional investors. 2.3% of Flora Growth shares are held by company insiders. Comparatively, 23.6% of Werewolf Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Werewolf Therapeutics had 11 more articles in the media than Flora Growth. MarketBeat recorded 11 mentions for Werewolf Therapeutics and 0 mentions for Flora Growth. Flora Growth's average media sentiment score of 0.00 beat Werewolf Therapeutics' score of -0.15 indicating that Flora Growth is being referred to more favorably in the media.

Company	Overall Sentiment
Flora Growth	Neutral
Werewolf Therapeutics	Neutral

Flora Growth currently has a consensus target price of $30.00, suggesting a potential upside of 557.89%. Werewolf Therapeutics has a consensus target price of $3.75, suggesting a potential upside of 879.11%. Given Werewolf Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Werewolf Therapeutics is more favorable than Flora Growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Flora Growth	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Werewolf Therapeutics	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

Flora Growth has higher revenue and earnings than Werewolf Therapeutics. Werewolf Therapeutics is trading at a lower price-to-earnings ratio than Flora Growth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Flora Growth	$57.61M	0.08	-$15.91M	-$32.49	N/A
Werewolf Therapeutics	$1.88M	9.90	-$60.82M	-$1.24	N/A

Summary

Werewolf Therapeutics beats Flora Growth on 9 of the 16 factors compared between the two stocks.

Get Flora Growth News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FLGC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FLGC vs. The Competition

Export

Metric	Flora Growth	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$4.77M	$8.30B	$6.48B	$12.36B
Dividend Yield	N/A	2.50%	2.67%	5.66%
P/E Ratio	-0.14	15.62	23.95	24.60
Price / Sales	0.08	6.04	536.37	171.61
Price / Cash	N/A	17.44	27.48	37.92
Price / Book	0.37	3.63	10.44	6.77
Net Income	-$15.91M	$224.06M	$3.56B	$337.32M
7 Day Performance	-5.39%	-0.96%	0.83%	2.06%
1 Month Performance	12.59%	5.02%	1.78%	3.93%
1 Year Performance	-84.25%	-0.78%	25.59%	32.29%

Flora Growth Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FLGC Flora Growth	N/A	$4.56 -6.7%	$30.00 +557.9%	-84.3%	$4.77M	$57.61M	N/A	280	Gap Down
XCUR Exicure	0.9807 of 5 stars	$2.85 -4.7%	N/A	-68.3%	$19.06M	$500K	N/A	50	Short Interest Decrease
MDCX Medicus Pharma	2.4719 of 5 stars	$0.32 -4.0%	$9.00 +2,689.0%	-87.0%	$19.05M	N/A	N/A	N/A	News Coverage Gap Down
KZIA Novogen	2.2325 of 5 stars	$11.42 +0.2%	$21.00 +83.9%	+53.5%	$18.85M	$30K	N/A	12
TPST Tempest Therapeutics	2.8193 of 5 stars	$1.27 flat	N/A	-80.9%	$18.81M	N/A	N/A	20	Positive News Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FLGC) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Flora Growth (FLGC) Competitors

FLGC vs. XCUR, MDCX, KZIA, TPST, and HOWL

How does Flora Growth compare to Exicure?

Summary

How does Flora Growth compare to Medicus Pharma?

Summary

How does Flora Growth compare to Novogen?

Summary

How does Flora Growth compare to Tempest Therapeutics?

Summary

How does Flora Growth compare to Werewolf Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FLGC vs. The Competition

Flora Growth Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Flora Growth (FLGC) Competitors

FLGC vs. XCUR, MDCX, KZIA, TPST, and HOWL

How does Flora Growth compare to Exicure?

Do analysts recommend XCUR or FLGC?

Do insiders & institutionals have more ownership in XCUR or FLGC?

Which has better earnings & valuation, XCUR or FLGC?

Which has more risk and volatility, XCUR or FLGC?

Does the media refer more to XCUR or FLGC?

Is XCUR or FLGC more profitable?

Summary

How does Flora Growth compare to Medicus Pharma?

Is MDCX or FLGC more profitable?

Which has more volatility & risk, MDCX or FLGC?

Do insiders and institutionals have more ownership in MDCX or FLGC?

Which has better valuation and earnings, MDCX or FLGC?

Does the media favor MDCX or FLGC?

Do analysts recommend MDCX or FLGC?

Summary

How does Flora Growth compare to Novogen?

Is KZIA or FLGC more profitable?

Which has preferable valuation and earnings, KZIA or FLGC?

Do analysts rate KZIA or FLGC?

Does the media prefer KZIA or FLGC?

Which has more volatility & risk, KZIA or FLGC?

Do insiders & institutionals believe in KZIA or FLGC?

Summary

How does Flora Growth compare to Tempest Therapeutics?

Which has preferable earnings & valuation, TPST or FLGC?

Do insiders and institutionals believe in TPST or FLGC?

Is TPST or FLGC more profitable?

Does the media favor TPST or FLGC?

Do analysts recommend TPST or FLGC?

Which has more volatility & risk, TPST or FLGC?

Summary

How does Flora Growth compare to Werewolf Therapeutics?

Is FLGC or HOWL more profitable?

Which has more volatility and risk, FLGC or HOWL?

Do insiders & institutionals hold more shares of FLGC or HOWL?

Does the media favor FLGC or HOWL?

Do analysts prefer FLGC or HOWL?

Which has better earnings and valuation, FLGC or HOWL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FLGC vs. The Competition

Flora Growth Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools